DE3739690A1
(de)
*
|
1987-11-24 |
1989-06-08 |
Hoechst Ag |
Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
|
IL88502A
(en)
*
|
1987-12-14 |
1993-04-04 |
Squibb & Sons Inc |
Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
HU222489B1
(hu)
*
|
1990-07-25 |
2003-07-28 |
Novartis Ag. |
Stabilizált gyógyszerkészítmények és eljárás az előállításukra
|
US6300361B1
(en)
|
1990-07-25 |
2001-10-09 |
Novartis Ag |
Stabilized pharmaceutical compositions comprising acid donors
|
US5292520A
(en)
*
|
1990-09-13 |
1994-03-08 |
Akzo N.V. |
Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
|
DE69104453T2
(de)
|
1990-09-13 |
1995-03-16 |
Akzo Nv |
Stabilisierte feste chemische Zusammensetzungen.
|
US5238935A
(en)
*
|
1991-05-20 |
1993-08-24 |
Schering Corporation |
N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
|
US5124337A
(en)
*
|
1991-05-20 |
1992-06-23 |
Schering Corporation |
N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
|
FR2665834B1
(fr)
*
|
1991-07-24 |
2001-02-23 |
Sandoz Sa |
Composition pharmaceutique stabilisee par un donneur d'acide chlorhydrique, et sa preparation.
|
TW284688B
(da)
*
|
1991-11-20 |
1996-09-01 |
Takeda Pharm Industry Co Ltd |
|
SI9111842A
(sl)
*
|
1991-11-25 |
1998-04-30 |
Krka |
Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
|
TW483763B
(en)
*
|
1994-09-02 |
2002-04-21 |
Astra Ab |
Pharmaceutical composition comprising of ramipril and dihydropyridine compound
|
US5573780A
(en)
*
|
1995-08-04 |
1996-11-12 |
Apotex Usa Inc. |
Stable solid formulation of enalapril salt and process for preparation thereof
|
US6296871B1
(en)
|
1998-04-12 |
2001-10-02 |
Ranbaxy Laboratories Limited |
Stable solid pharmaceutical compositions containing enalapril maleate
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
HUP0102260A3
(en)
*
|
1998-06-05 |
2002-12-28 |
Warner Lambert Co |
Stabilization of compositions containing ace inhibitors using magnesium oxide
|
NZ333206A
(en)
*
|
1998-12-08 |
2000-07-28 |
Bernard Charles Sherman |
Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
|
US20030027837A1
(en)
*
|
1998-12-08 |
2003-02-06 |
Sherman Bernard Charles |
Pharmaceutical compositions comprising quinapril magnesium
|
US6637359B1
(en)
*
|
1998-12-15 |
2003-10-28 |
Maritrans Inc. |
System and method for internally fitting a new inner hull to an existing outer hull to form a rebuilt double hull vessel
|
US6060461A
(en)
*
|
1999-02-08 |
2000-05-09 |
Drake; James Franklin |
Topically applied clotting material
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
WO2001015674A2
(en)
*
|
1999-08-30 |
2001-03-08 |
Aventis Pharma Deutschland Gmbh |
Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
|
US6555551B1
(en)
|
1999-08-31 |
2003-04-29 |
Mutual Pharmaceutical Co., Inc. |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US20030225124A1
(en)
*
|
1999-08-31 |
2003-12-04 |
Spiridon Spireas |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US6764694B1
(en)
*
|
1999-08-31 |
2004-07-20 |
Mutual Pharmaceutical Co., Inc. |
Stable formulations of ACE inhibitors, and methods for preparation thereof
|
US20040157911A1
(en)
*
|
1999-08-31 |
2004-08-12 |
Spiridon Spireas |
Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
|
GB0001621D0
(en)
|
2000-01-26 |
2000-03-15 |
Astrazeneca Ab |
Pharmaceutical compositions
|
CA2303481A1
(en)
*
|
2000-04-05 |
2001-10-05 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising moexipril magnesium
|
US6333332B1
(en)
*
|
2000-08-25 |
2001-12-25 |
Impax Laboratories, Inc. |
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
TWI232102B
(en)
*
|
2001-07-17 |
2005-05-11 |
Shionogi & Co |
A pharmaceutical formulation for injection
|
US20040170689A1
(en)
*
|
2001-11-09 |
2004-09-02 |
Odink Debra Alida |
Stabilized formulations comprising hydrolytically unstable compositions
|
AU2003235579A1
(en)
*
|
2002-01-15 |
2003-07-30 |
Delta Hf. |
Formulations of quinapril and related ace inhibitors
|
US20050202081A1
(en)
*
|
2002-01-15 |
2005-09-15 |
Deepak Bahl |
Stable pharmaceutical compositions comprising ace inhibitor(s)
|
US20030157165A1
(en)
*
|
2002-02-01 |
2003-08-21 |
Sherman Bernard Charles |
Stable saccharide-free tablets comprising a salt of quinapril or moexipril
|
US20030215526A1
(en)
*
|
2002-03-08 |
2003-11-20 |
Scott Stofik |
Stable formulations of angiotensin converting enzyme (ACE) inhibitors
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
CA2530788C
(en)
*
|
2003-06-26 |
2010-02-09 |
Teva Pharmaceutical Industries Ltd |
Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
|
US6869963B2
(en)
*
|
2003-07-11 |
2005-03-22 |
Sandoz Ag |
Stable pharmaceutical compositions containing an ACE inhibitor
|
WO2005027881A2
(en)
*
|
2003-09-23 |
2005-03-31 |
Texcontor Etablissement |
Stable quinapril compositions
|
US20050181055A1
(en)
*
|
2003-10-08 |
2005-08-18 |
Mathur Rajeev S. |
Pharmaceutical compositions of quinapril
|
AU2003300692A1
(en)
*
|
2003-10-30 |
2005-05-19 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
GB2411355B
(en)
|
2004-02-27 |
2006-02-22 |
Niche Generics Ltd |
Pharmaceutical composition
|
US20080234353A1
(en)
*
|
2004-03-24 |
2008-09-25 |
Reynir Eyjolfsson |
Formulations of Ramipril
|
ES2603856T3
(es)
*
|
2004-03-29 |
2017-03-01 |
Les Laboratoires Servier |
Procedimiento para preparar una composición farmacéutica sólida
|
SI21800A
(sl)
|
2004-05-14 |
2005-12-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Nov postopek sinteze perindoprila
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
GR1006875B
(el)
*
|
2005-06-30 |
2010-07-12 |
"Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., |
Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
|
GB0518129D0
(en)
*
|
2005-09-06 |
2005-10-12 |
Arrow Int Ltd |
Ramipril formulation
|
GB2431579A
(en)
*
|
2005-10-28 |
2007-05-02 |
Arrow Int Ltd |
Ramipril formulations
|
US20070098782A1
(en)
*
|
2005-10-28 |
2007-05-03 |
Selamine Limited |
Ramipril Formulation
|
PL1948224T3
(pl)
|
2005-11-17 |
2014-10-31 |
Silverstone Pharma Est |
Trwały preparat amorficznych soli peryndoprylu, sposób ich wytwarzania, zwłaszcza wytwarzania w skali przemysłowej oraz ich zastosowanie w terapii nadciśnienia
|
EP1815857A1
(en)
|
2006-02-02 |
2007-08-08 |
LEK Pharmaceuticals D.D. |
A pharmaceutical composition comprising perindopril
|
US20070232680A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Vijayabhaskar Bolugoddu |
Preparation of ramipril and stable pharmaceutical compositions
|
US7943655B2
(en)
*
|
2006-04-05 |
2011-05-17 |
Universitat Zurich |
Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CN102838599A
(zh)
|
2006-05-04 |
2012-12-26 |
贝林格尔.英格海姆国际有限公司 |
多晶型
|
US20100035955A1
(en)
*
|
2006-06-30 |
2010-02-11 |
Panagiotis Keramidas |
Stabilised Composition Comprising ACE Inhibitors
|
GB0624084D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril amino acid salts
|
GB0624087D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril combination salt
|
GB0624090D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril amine salts
|
NZ600126A
(en)
*
|
2007-08-17 |
2013-12-20 |
Boehringer Ingelheim Int |
Purine derivatives for use in the treatment of fap-related diseases
|
JP2009084242A
(ja)
*
|
2007-10-02 |
2009-04-23 |
Nichi-Iko Pharmaceutical Co Ltd |
安定性に優れた塩酸テモカプリル錠剤
|
JP5113476B2
(ja)
*
|
2007-10-09 |
2013-01-09 |
沢井製薬株式会社 |
保存安定性に優れた塩酸テモカプリルの錠剤
|
CN101854932A
(zh)
*
|
2007-11-07 |
2010-10-06 |
詹森药业有限公司 |
包含血管紧张素转化酶抑制剂和加压素受体拮抗剂的组合疗法
|
WO2009113081A1
(en)
*
|
2008-03-10 |
2009-09-17 |
Lupin Limited |
Tris (hydroxymethyl ) amino methane salt of quinapril and ramipril
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
AU2009281122C1
(en)
*
|
2008-08-15 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
TR200906322A2
(tr)
|
2009-08-17 |
2011-07-21 |
Bi̇lgi̇ç Mahmut |
Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
|
ES2364011B1
(es)
|
2009-11-20 |
2013-01-24 |
Gp Pharm, S.A. |
Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
|
KR102668834B1
(ko)
|
2009-11-27 |
2024-05-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
EP2585051B2
(en)
*
|
2010-06-23 |
2020-04-08 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
|
KR20230051307A
(ko)
|
2010-06-24 |
2023-04-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
EP2654729B1
(en)
|
2010-12-24 |
2016-05-04 |
KRKA, d.d., Novo mesto |
Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EA030121B1
(ru)
|
2011-07-15 |
2018-06-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Замещенные хиназолины, их получение и их применение в фармацевтических композициях
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US8568747B1
(en)
|
2012-10-05 |
2013-10-29 |
Silvergate Pharmaceuticals, Inc. |
Enalapril compositions
|
PL227900B1
(pl)
|
2012-11-15 |
2018-01-31 |
Adamed Spolka Z Ograniczona Odpowiedzialnoscia |
Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
|
US9937153B2
(en)
|
2013-08-30 |
2018-04-10 |
Merck Sharp & Dohme Ltd. |
Oral pharmaceutical formulation of omarigliptin
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
DK3193826T3
(da)
|
2014-07-31 |
2019-02-11 |
Pharmathen Sa |
Orodispergerbar filmsammensætning, der omfatter enalapril til behandling af hypertension hos en pædiatrisk population
|
SI3524595T1
(sl)
|
2014-08-28 |
2022-10-28 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistosti in postopek njegove proizvodnje
|
WO2016136745A1
(ja)
|
2015-02-25 |
2016-09-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体の苦味抑制方法
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
US9463183B1
(en)
|
2015-10-30 |
2016-10-11 |
Silvergate Pharmaceuticals, Inc. |
Lisinopril formulations
|
WO2017077425A1
(en)
|
2015-11-07 |
2017-05-11 |
Ftf Pharma Private Limited |
Oral solution of ace inhibitors
|
US9669008B1
(en)
|
2016-03-18 |
2017-06-06 |
Silvergate Pharmaceuticals, Inc. |
Enalapril formulations
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|